This article is more than 5 years old. Information may no longer be current.

Johnson & Johnson announces ruling related to its infliximab biosimilar

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Johnson & Johnson announced the District of Massachusetts Federal Court issued a ruling on the summary judgment motion filed by Celltrion Healthcare Co. Ltd., Celltrion Inc. and Hospira Healthcare Corporation in the infringement lawsuits filed by Janssen Biotech Inc. regarding Remicade.

According to the release, the court ruled in favor of Celltrion and Hospira, noting that U.S. Patent No. 6,284,471 for Remicade is invalid. Janssen reportedly plans to appeal the court’s decision in the federal circuit and will also continue the appeal process in proceedings related to the patent through the U.S. Patent & Trademark Office. The company awaits a date for the oral hearing for the appeal.

“Janssen will continue to defend its intellectual property rights relating to its innovative medicines. A commercial launch of an infliximab biosimilar prior to the outcome of the appeals would be considered an at-risk launch,” the release noted.

Reference:

www.jnj.com